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Objective: The present study was aimed on formulation and evaluation of famotidine loaded niosomal formulation for in vitro and in vivo 
pharmacokinetic behaviour. Formulating it as niosomal formulation might be quite advantageous for prolonging the duration of pharmacological 
action and improved bioavailability. 
Methods: In the present study niosomal formulations were prepared by using most documented thin film hydration technique by using various grades 
of surfactants (span 20, 40, 60, 80) in varying ratios with cholesterol, negative charge inducer di cetyl phosphate (DCP) and drug famotidine. Suitable 
preformulation studies were conducted like identification of drug, excipient and drug compatibility study. The optimized drug loaded niosomes were 
characterized for size and morphology, polydispersity index, zeta potential, drug entrapment, in vitro release, in vivo study and stability study. 
Results: The results showed that the vesicles formed were spherical in shape, size ranging between 160.1 nm to 718.7 nm with zeta potential 
values indicating good stability and formulation containing span 60 (NMS7) showed the highest entrapment efficiency (73.234%). All the 
formulations showed prolonged release profile for more than 24 h with release kinetics better suited to zero order release pattern. In vivo study 
conducted on rabbits predicted a fourfold increase in pharmacokinetic parameter (area under curve)AUC and pharmacological action for more than 
24 h as compared to free drug famotidine which showed its action only upto 12 h. 
Conclusion: Thus the famotidine loaded niosomal formulation may be considered as a very promising drug delivery system which could be 
successfully employed for prolonging the drug release and overcoming the drawbacks of conventional drug delivery systems. 
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INTRODUCTION 
In recent years transporting the drug molecule to desired site in the 
biological system has become a very sophisticated area of 
pharmaceutical research, the role of novel drug delivery is not only 
limited to ease of administration and convenience but along with 
this it is also needed to provide better pharmacological effect along 
with reduced side effects. These novel carriers provide sustained 
drug release for prolonged duration thus resulting in enhanced 
therapeutic efficacy and minimized side effects [1]. 
From the last few years, liposomes have attracted a great attention 
in the delivery of drugs because of the many advantages, e. g. they 
are biodegradable, non-toxic, amphiphilic in nature, penetration 
enhancers and effective in the modulation of drug release 
properties. But liposomes exhibit some difficulties, including the 
instability of aqueous dispersions on storage and the leakage of the 
encapsulated drugs, the high cost of synthetic phospholipids and 
variable purity of natural phospholipids. An alternative approach 
that overcomes several of these problems associated with liposomes 
involves formation of liposome-like vesicles (niosomal dispersions) 
from non-ionic surfactants, commonly referred as niosomes [2]. 
These niosomal dispersion are formed from self-assembly of 
hydrated synthetic non-ionic surfactant monomers which are 
capable of entrapping a wide variety of drugs both hydrophilic and 
hydrophobic, can be delivered by various routes like oral, 
transdermal, parenteral, occular [3] and have been considered 
superior to microspheres, nanoparticles, liposomes and other 
carriers in terms of better entrapment of drugs, better target site 
specificity and in handling burst effect of drug release [4, 5]. 
Niosomes have also shown advantages as drug carriers, such as 
being low cost and chemically stable as compared to liposomes [6]. 
Famotidine is a potent H2 receptor antagonist. It is widely 
prescribed in gastric ulcers, duodenal ulcers, zollinger Ellison 
syndrome and gastro oesophageal reflux disease. Compared with 
other drugs of this class it is 7.5 to 20 times more potent than 
ranitidine and cimetidine respectively [7]. Inspite of its benefits it 
suffers from low and variable bioavailability which is 20–40 % and 
short biological half-life (2.5–4h). Conventional formulations of 20 
mg dose can inhibit gastric acid secretion hardly upto 5 to 7 h. 
Thus formulating it into niosomal formulation is expected to 
provide a prolonged pharmacological effect with reduced dosing 
frequency and better patient compliance by reducing the peak and 
valley curves in the plasma drug concentration profile. It is also 
expected to provide some local effect on the stomach and small 
intestine [8]. Thus the aim of the present research was to prepare 
drug loaded niosomes of famotidine for oral controlled release by 
using different grades of span like Span 20,40,60,80 by thin film 
hydration technique and also optimizing the different process 
variables and further its characterization by various In vitro and In 
vivo methods. 
MATERIALS AND METHODS 
Famotidine was obtained as gift sample from Glenmark 
Pharmaceutical Ltd (India), various other chemicals like cholesterol 
was purchased from Loba Chemie Pvt. Ltd. (India), chloroform, 
methnol, Span 20,40,60,80 were obtained from Central Drug House, 
Delhi, (India), di cetyl phosphate (DCP) was purchased from Sigma 
Aldrich, and dialysis membrane from Himedia (India). All chemicals 
used in the study were of analytical grade. 
Identification of drug 
Ultraviolet spectroscopy 
UV Spectral Analysis was carried out for the identification of 
famotidine. Different concentrations of Famotidine in the range 2 to 
20 µg/ml were scanned for λmax between 200-400 nm using Double 
Beam Spectrophotometer (Shimadzu UV-1700 series).  
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Fourier transforms infrared spectroscopy (FTIR) 
FTIR spectra of famotidine, from 4000 cm-1 to 450 cm-1
Method of preparation 
, was 
obtained using FTIR spectrophotometer (Perkin Elmer) according to 
KBr pellet method and compared with standard reference spectra of 
famotidine. The drug excipients interaction study was also carried 
out by IR spectroscopy. The IR spectrum of combination of drug and 
various excipients to be used in the formulation was obtained using 
FTIR spectrophotometer and compared with the individual spectra 
of drug and excipients to investigate any interactions. Spectral 
analysis using IR helped to identify any modification in the 
characters of the formulation when it was mixed with the non-drug 
substances [9]. 
Solubility 
To obtain a desirable concentration of the drug in blood, solubility 
plays a major role (Baby et al. 2012) Solubility studies of famotidine 
were carried out in distilled water, 0.1N HCl(pH 1.2) and phosphate 
buffer (pH 7.4). Saturated solutions were prepared in screw capped 
tubes by adding excess drug to the solvents and shaking on the 
shaker (Jyoti Scientific Industry, Gwalior) for 24 h at 25±0.5 °C. The 
solutions were then filtered, diluted and analyzed by UV Spectro-
photometer (Shimadzu UV-1700 series, Japan). The determinations 
were made in triplicate shown in (table 1).  
In the present study, niosomal formulations were prepared by thin 
film hydration technique as reported earlier with slight 
modifications [10] by using different grades of span (span 20, span 
40, span 60, and span 80) at various cholesterol: surfactant ratios, 
given in (table 2) (Where NML is (batch A) containing span 20, NMP 
is (batch B) containing span 40, NMS is (batch C) containing span 60 
and NMO is (batch D) containing Span 80). DCP was added to the 
formulation that acts as a negative charge inducer which provides 
more efficient drug delivery and keeps the niosomal formulation 
stable for long period of time. Accurately weighted quantities of 
surfactants, cholesterol and drug were taken and were dissolved in 
chloroform–methanol mixture in a round bottom flask and DCP was 
added to the above mixture. The chloroform methanol mixture was 
evaporated in a rotary flask evaporator under a vacuum at 
temperature of 60 °C at 120 rpm until a smooth, dry lipid film was 
obtained. 
Further preparation flask was kept in vacuum desiccators overnight 
for complete removal of chloroform and mehanol as discussed by 
[11]. Then film was hydrated with aqueous phase (PBS pH 7.4) for 3 
hr at room temperature with shaking. The niosomal suspension was 
kept at 2–8 °C for 24hr. These preparations were optimized on the 
basis of entrapment efficiency. 
 
Table 2: Composition of niosomal formulations with different grades of span at varying concentration of surfactant and cholesterol 
Formulation code Surfactant (Mg) Cholesterol (mg) DCP (Mg) Chloroform/ methanol Drug (mg) 
NMLa1/NMPb1/NMSc1/NMOd 100 1 - - 1:4 5 
NML2/NMP2/NMS2/NMO2 90 10 - 1:4 5 
NML3/NMP3/NMS3/NMO3 80 20 - 1:4 5 
NML4/NMP4/NMS4/NMO4 70 30 - 1:4 5 
NML5/NMP5/NMS5/NMO5 60 40 - 1:4 5 
NML6/NMP6/NMS6/NMO6 50 50 - 1:4 5 
NML7/NMP7/NMS7/NMO7 47.5 47.5 5 1:4 5 
NML8/NMP8/NMS8/NMO8 60 30 10 1:4 5 
NML9/NMP9/NMS9/NMO9 50 30 20 1:4 5 
aNML is batch containing span 20, b NMP is batch containing Span 40,c NMS is batch containing span 60 and d
 
NMO is batch containing span 80 
Particle shape and morphology by transmission electron 
microscopy (TEM) 
The shape and morphology of prepared optimized niosomes were 
evaluated by optical microscopy and by Transmission electron 
microscopy (Jeol JEM1400 Tokyo Japan) at Central Drug Research 
Institute (CDRI Lucknow). 
Scanning electron microscopy (SEM) 
The vesicle formation were examined by scanning electron 
microscopy (Carl ZEISS microscopy Ltd) at central instrument 
facility at (Banaras Hindu university) IIT-BHU), in order to 
determine size, shape and lamellarity.  
Entrapment efficiency 
An aliquot of the freshly prepared purified niosomal dispersion (5 
mg/ml) was diluted with 10%Triton X-100 in a ratio of 1:99 vol/vol 
for 5 min. The detergent dissolved the niosomes and yielded a clear 
solution. The resultant was centrifuged to get a clear supernatant. 
The supernatant was suitably diluted with phosphate buffer and 
analysed for Famotidine concentration using UV spectrophotometer 
at λmax.266 nm to calculate the amount of entrapped drug. The 
Percentage of entrapped Famotidine was calculated by applying the 
following equation [12, 13]. 
Entrapment efficiency % =
amount of entrapped drug
Initial amount of drug added
× 100 
Vesicle size, zeta potential and polydispersity index determination 
Niosomal suspension was characterized for vesicle size and vesicle 
size distribution of the multilamellar vesicles by using Beckman 
coulter delsaTM
In vitro drug release study 
 nano zeta potential and submicron particle size 
analyser at central instrument facility of (IIT-BHU, India). Zeta 
potential, Size, size distribution measurements and polydispersity 
index measurements were obtained automatically as the instrument 
is microprocessor controlled. The instrument uses Photon 
correlation spectroscopy(PCS) to determine the particle size where 
as it uses electrophoretic light scattering (ELS) to determine 
electrophoretic movement of charged particles under an applied 
electric field from Doppler shift of scattered light, for zeta potential 
determination. 
The In vitro release of famotidine from the prepared niosomes was 
carried by membrane diffusion method [14, 15]. The drug release 
study was carried out using dialysis membrane. Measured amount of 
niosomes were placed in the cylinder. This cylinder was fitted at its 
lower end with dialysis membrane which served as the donor 
compartment. The glass cylinder was attached to the shaft of the 
dissolution apparatus and then suspended in the dissolution flask of 
USP dissolution apparatus paddle type containing 500 ml of 
phosphate buffer (pH 7.4) maintained at 37 °C which served as the 
receptor compartment and aliquots were withdrawn at intervals of 
2h for 24h. At each sampling time, the volume of receptor 
compartment was maintained with equal volume of phosphate 
buffer, pH 7.4 or 0.1 N HCL to maintain the sink condition during the 
whole study. The drug in withdrawn samples was estimated by UV 
spectrophotometer (Shimadzu UV-1700 series, Japan) at λmax 266 
nm. All assessments were completed in triplicate [16].  
Release kinetics 
For the statistical analysis, four principally practised mathematical 
models were chosen for the estimation of release kinetics of drug 
from famotidine loaded niosomes ie. Zero order (Eq.1), First order 
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(Eq.2), HiguChi square root model (Eq.3) and Kosmeyer Peppas 
model (Eq.4) 
C = C0 − K0t …… (1) 
log C = logC0 − kt/2.303 …… (2) 
Q = kHt1/2 …… (3) 
 Mt/M∞ = ktn …… (4) 
Where C and Q is the amount of drug released at time t, C0 is the initial 
concentration of drug, Mt/M∞ is the fraction of drug released at time t 
and k0, k, kHare the corresponding rate constants,, n is the diffusional 
release exponent that could be used to characterize the different 
release mechanism (n ≤ 0.45) fickian diffusion, (0.45<n<1) anomalous 
transport and (n=1) case II transport, zero order release [17-19]. 
Data obtained from drug release assessment were treated 
complimenting zero order (cumulative amount of drug release vs time), 
first order (log cumulative percentage of drug remaining vs time), 
Higuchi (cumulative percentage of release vs square root of time) and 
Kosmeyer–Peppas (log cumulative percentage of drug released vs log 
time) equation models. Excel 2007 was used to evaluate the results of in 
vitro drug release to acquire the best fit kinetic model for drug release 
from prepared niosomal formulation [20]. 
In vivo study 
Nine male white Newzealand rabbits weighing an average weight of 
2.5 kg were selected for the study. The study protocol was 
approaved by the Institutional Animal Ethical Committee 
registration no: BU/Pharm/IAEC/a/16/14 for the use of animals in 
research. The rabbits were fasted overnight or for twelve hours with 
free access to water. On study days, rabbits were placed in metal 
restrainers at 9.00 am. Doses were administered orally by gavage at 
9.00 am as 4 ml bolus of the respective formulations [21]. The 
studied formulations were free famotidine solutions in normal saline 
and the freshly prepared niosomal formulations (4 ml) containing 
both free and entrapped drug. Blood samples were collected at 
1,2,4,6,8,10, 12, and 24 h after administration of free famotidine 
solution and at 1,2,4,6,8,10,12 and 24 h after administration of 
famotidine niosomal dispersion. The experiment were carried out on 
same rabbits in which atleast two weeks passed between each 
application inorder to obtain complete washout of drug.  
Blood sample, 2 ml each were collected from the marginal ear vein of 
the rabbits, into heparinised centrifuge tubes just before dosing and 
at 1,2,4,6,8,10,12,24 h during the study. Blood samples were 
centrifuged at 1500rpm and the plasma was separated. One undosed 
plasma sample was kept as a blank. To one ml of each of the other 
plasma samples, 5 ml of acetonitrile (to precipitate blood proteins) 
was added, the tubes were then centrifuged at 2500 rpm for 15 min, 
4 ml of the supernatant was pippetted out, to which 0.2 ml of 1.47 M 
perchloric acid was added and the drug concentration was 
determined by UV Spectroscopy at 258 nm. The blank consist of 1 ml 
undosed plasma, 4 ml acetonitrile and 0.2 ml of 1.47 M perchloric 
acid (to precipitate plasma proteins) [22]. 
The calibration curve of famotidine was prepared as follows: 
Famotidine solutions in acetonitrile were prepared at concentration 
of 1-10µg/ml. One millilitre of this solution was made up to 5 ml 
with acetonitrile. To each of this solution 1 ml of plasma from 
undosed rabbit blood was added and contents were centrifuged at 
2500 rpm for 15 min. Supernatant (4 ml) was then pippetted out to 
which 0.2 ml of 1.47 M perchloric acid was added and the 
absorbance was measured atλmax 258 nm. The blank was prepared 
using plasma from the undosed animal, acetonitrile and perchloric 
acid in exactly the same way as the calibration curve for famotidine 
was plotted as absorbance at λmax
Stability studies 
 258 nm versus concentration was 
linear over the range of 1-10 µ/ml with the correlation coefficient of 
0.999 [23]. 
Drug leakage studies 
The multilamellar vesicles prepared by thin film hydration were 
subjected to stability studies. After measuring the initial percentage 
entrapment of the drug in formulations, four batches of the same 
formulation were stored in sealed glass ampoules (1 each) at 4±2℃, 
25±2℃, 37±2℃ for a period of atleast one month. After every seven 
days, percentage entrapment of drug was determined in the 
formulation to know the amount of drug leaked out. The percentage 
drug lost was calculated taking the initial entrapment of drug as 
100%. Plain niosomal suspension (without drug) prepared and 
stored in the same way, served as blank for this purpose, also after 
each week the formulation was observed microscopically and 
visually to check for the number of disrupted vesicles (in a constant 
area of slide visualized through microscope) and for their 
sedimentation and aggregation behaviour. 
RESULTS AND DISCUSSION 
Identification of drug by ultraviolet spectroscopy 
UV spectrum of famotidine was obtained by scanning Different 
concentrations of Famotidine in the range 2 to 20 µg/ml between 
200-400 nm using Double Beam Spectrophotometer (Shimadzu UV-
1700 series). The λmax was found to be 266 nm. 
Identification of drug by IR spectroscopy 
The IR spectrum of pure drug famotidine showed characteristic 
peaks at (3506.10, 3401.17) for N-H stretching, (1329.91Asy, 
1145.70 Sym) stretching vibration for sulphones, (2936.98) C-H 
stretching, (1643.57) N─H Bending, (1534.10) N -H Bending (NH2-
SO2
Preliminary solubility study of drug famotidine was conducted in 
various solvents like distilled water, 0.1N HCl and phosphate buffer 
PBS pH 7.4 which showed that its solubility in 0.1 N HCl was 
appreciable. The results are shown in table 1. 
) which matched with the reference spectra thus confirming the 
purity of the compound. The drug excipient interaction study 




Table 1: Solubility of famotidine in various solvents 
S. No. Solvents *Solubility (mg/ml)) 
1. Distilled water 0.367±0.071 
2. PBS pH 7.4  0.566±0.211 
3. 0.1 N HCl 7.442±0.312 
(*All values are expressed as mean n=3, ±SD: standard deviation) 
 
Particle shape and morphology by TEM 
The preliminary information regarding the shape and morphology of 
niosomal formulation was determined by optical microscopy which 
revealed the spherical shape of niosomes but unfortunately the 
information concerning microstructure of noisome could not be 
visualized due to low magnification power of microscope. Therefore 
TEM was employed to elucidate morphology of the niosomal 
vesicles. TEM photo micrographs confirm that the niosomes have a 
closed spherical shape shown in fig. 1. The size range of the 
prepared niosomes was in nano range. 
Scanning electron microscopy 
The SEM photomicrographs of famotidine loaded niosomes (fig. 2) 
revealed spherical shape of niosomes with no aggregation of vesicles 
and the size range was found to be in nanometer which is well suited 
for oral delivery of famotidine loaded niosomes. 
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Fig. 1: TEM photomicrographs of famotidine loaded niosomal formulation 
 
 
Fig. 2: SEM images of famotidine loaded niosomal formulation 
 
Entrapment efficiency 
On the basis of entrapment efficiency values for all the prepared 
batches of famotidine loaded niosomes, formulations NML7, NMP7, 
NMS7 and NMO7 were selected as optimized formulations as they 
showed better % entrapment as compared to other batches. 
Famotidine encapsulation efficiency of optimized formulations are 
given in (table 3) which clearly shows that the formulation 
containing span 60 showed the highest entrapment efficiency of 
73.234% followed by span 40 and span 20 containing formulation ie. 
71.308 % and 69.333% respectively. While span 80 containing 
formulation showed the least entrapment efficiency ie. 65.086% 
these results were in accordance with previous study done by Hao 
and Li (2011) [25], this could be attributed to the structure, 
orientation and packing behaviour of the surfactant. Span 20, 40 and 
60 have the same head group but different alkyl chain but span 80 
has an unsaturated alkyl chain. The introduction of double bonds 
made the chain bend. This means that the adjacent molecules cannot 
be tight when they form membrane of niosomes. This caused the 
membrane to be more permeable which possibly explains the low 
entrapment efficiency behaviour. While span 60 has the longest 
saturated alkyl chain due which it showed highest entrapment 
efficiency. The increase in the alkyl chain length of different grades 
of span led to increase in the encapsulation efficiency (%EE) [24, 
25]. The higher entrapment in case of span 60 can also be due to the 
solid nature, hydrophobicity and high phase transition temperature 
of the span60 [26]. Spans 60 with the highest transition temperature 
(Tc = 53 °C) amongst all spans (16 °C for span 20, 42 °C for span 40 
and-12 °C for span 80) [27]. Exhibit highest entrapment efficiency 
[28]. Gel transition temperature of span increases as the length of 
acyl chain increases. For example span 20 with 9 carbon atoms in 
the carbon chain is liquid at room temperature [29]. Interestingly 
with increasing carbon chain length entrapment efficiency increases 
[30]. Moreover HLB of the surfactant also affects the entrapment 
efficiency, as it was observed that lower the HLB of the surfactant 
higher was the entrapment efficiency and stability. In the present 
research niosomes prepared using span 60 (HLB 4.7) exhibited 
higher entrapment as compared to span 20 with higher HLB value 
(HLB 8.6) [31, 32]. 
Vesicle size, zeta potential and polydispersity index  
On the basis of above findings the formulation NML7, NMP7, NMS7 
and NMO7 were selected for further studies. The vesicle size of 
various developed niosomal formulations with various grades of 
span were determined by submicron particle size analyser. It was 
clearly observed from the results that the mean vesicle size of 
niosomes containing span 20 were found to be higher as compared 
to other niosomal formulations containing span 40,60 and 80. The 
vesicle size of niosomal formulation were obtained in the range of 
160.1±69.7 nm to718.7±749.9 nm (given in table 3) The vesicle size 
of niosomes decreased consistently from span 20 to span 80 and are 
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found in the following order-span 20>span 40>span60>span 80 
which was in conformance with Asthana et al. (2016) [5]. 
This might be due to increase in hydrophobicity of the surfactant from 
span 20 to span 80. The decrease in surface free energy with 
increasing hydrophobicity of surfactant may be the major reason for 
reduction in the particle size of niosomes [33]. The zeta potential 
values (table 3) indicate that all the optimized formulations have good 
stability, it was also observed that highest zeta potential values were 
obtained in case of span 20 formulation whereas lowest zeta potential 
for span 80 formulation which could also be due to increase in 
hydrophobicity of surfactant (Balakrishnana et al. 2009) [10]. 
Polydispersity index PDI is used to describe the degree of non-
uniformity of a size distribution of particles. Also known as the 
hererogeneity index. This index is dimensionless and scaled such 
that values smaller than 0.05 are mainly seen with highly 
monodisperse standard. PDI value bigger than 0.7 indicate that the 
sample has a very broad particle size distribution. The numerical 
value of PDI ranges from 0.0 for perfectly uniform sample with 
respect to particle size whereas a value approaching 1.0 represents a 
highly polydisperse sample with multiple particle size populations. 
In drug delivery applications using lipid based carriers such as 
liposomes and niosomes formulations, a PDI of 0.3 and below is 
considered to be acceptable and indicates a homogenous population 
of phospholipid vesicles [34-36] The optimized niosomal 
formulations showed polydispersity index in the range of 0.114 to 
0.514 given in (table 3) indicating the homogeneity of the 
formulations.
 
Table 3: Percentage entrapment efficiency, vesicle size, polydispersity index and zeta potential values of optimized niosomal 
formulations of famotidine 
Formulation code *%Entrapment *vesicle size (nm) Polydispersity index Zeta potential 
NML7 69.333±0.925 718.7±749.9 0.514 -57.45 
NMP7 71.3085±0.688 487.6±52.1 0.114 -49.02 
NMS7 73.234±0.365 236.1±65.3 0.274 -44.99 
NMO7 65.086±0.938 160.1±69.7 0.295 -41.04 
(*All values are expressed as mean n=3, ±SD: standard deviation) 
 
Drug release profile of optimized famotidine loaded niosomal 
formulation 
The in vitro release study (fig. 3) are often performed to predict how 
a delivery system might work in ideal conditions and this might also 
give some indication of its in vivo performance. In present research 
famotidine encapsulated niosomes were analysed for its in vitro 
release in 0.1 N HCl and in phosphate buffer pH 7.4 which showed 
constant drug release with no burst effect indicating that the drug 
was homogeneously dispersed and there was no significant amount 
of drug adsorbed onto the surface of niosomal vesicles. Whereas the 
free drug elicited a fast drug release ie. 74.625 % just after 1 h as 
compared to niosomal formulations which showed drug release upto 
5% after 1 h. The free drug solution began to plateau only after 4 h 
but the optimized niosomal formulations continued to show drug 
release for more than 24 h without reaching plateau. This is 
indicative of rate controlling nature of niosomes as lipid bilayers 
serve as barrier for drug release. 
 
 
Fig. 3: Drug release profile of optimized niosomal formulation of famotidine (all values are expressed as mean n=3) 
 
Data treatment 
Inorder to study the mechanism of drug release from the niosomal 
formulation the in vitro release study data were fitted to various 
mathematical models. The kinetic models used were zero order, 
first order, Higuchi’s square root of time and Kosmeyer and 
Peppas model (table 4). Famotidine release from niosomal 
formulation showed a better fit to zero order release pattern 
furthermore the release pattern when fitted to Kosmeyer Peppas 
model showed release exponent (n) values ranging from 0.567 to 
0.598 which were close to Fickian diffusion pattern. Whereas 
Formulation with Span 20 showed n value ie 0.618 thus it follows 
anomalous diffusion mechanism. 
In vivo study 
On the basis of in vitro characterization results NMS7 formulation 
was found to be the most satisfactory one and hence it was selected 
for further in vivo study. The concentration of drug in plasma at 
different time interval was determined spectrophotometrically (fig. 
4). Different pharmacokinetic parameters such as Cmax (maximum 
concentration of the drug in the blood), Tmax (the time it takes for a 
drug to reach Cmax) and AUC area under curve were calculated from 
the data and the results are represented in (table 5). Analysis of 
variance (ANNOVA) was employed in the statistical analysis of the 
determined parameters in this study by using the software SYSTAT 
12. The obtained results indicate a *P value = 0.03 which is less than 
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0.05 which clearly indicate that the differences are statistically 
significant with a *P value<0.05. These clearly indicate a fourfold 
increase in the area under curve of prepared niosomal formulation 
of famotidine as compared to free drug solution. This indicate that 
the niosomal formulation provided prolonged and controlled 
delivery of drug without any sharp peaks and troughs. Thus besides 
increasing the patient compliance because of once a day 
administration, the optimized formulation will be able to reduce the 
incidence of problems reported due to sharp rise and fall in plasma 
drug concentrations of famotidine. 
 
Table 4: Release rate constant (K) and correlation coefficient (R2
Formulation 
code 
) obtained after treating the release profile according to various 
mathematical models 
Zero order First Order Higuchi’s square root Kosmeyer Peppas 
*K *R0 *K2 *R1 *K2 *RH  *K2 *Rk 2 
NML7 0.0603±0.0007 0.992±0.001 0.0011±0.000 0.641±0.008 2.3067±0.0243 0.912±0.004 0.780±0.013 0.950±0.007 
NMP7 0.0534±0.0007 0.994±0.001 0.0010±0.000 0.636±0.007 2.0495±0.0238 0.919±0.003 0.795±0.011 0.955±0.005 
NMS7 0.0510±0.0004 0.998±0.001 0.0011±0.000 0.676±0.005 1.9306±0.0145 0.897±0.004 0.761±0.020 0.934±0.012 
NMO7 0.0663±0.0003 0.985±0.000 0.0011±0.000 0.608±0.009 2.5704±0.0171 0.928±0.004 0.811±0.013 0.965±0.005 
(*All values are expressed as mean n=3, ±SD: standard deviation) 
 
 
Fig. 4: Plasma drug concentration profile of pure drug famotidine and prepared niosomal formulation NMS7 of famotidine values 
represented as mean±SD (n=3) and values are statistically significant *P<0.05 
 
Table 5: Pharmacokinetic parameters of drug determined after administration of free drug solution and niosomal formulation 
S. No. Pharmacokinetic parameters Free drug NMS7 
1. *C 10.427±0.74 µg/ml max 14.568±1.24 µg/ml 
2. t 4 h max 10 h 
3. AUC 61.55µg/ml h 242.765 µg/ml h 
*values are expressed as mean n=3,±SD: standard deviation 
 
Stability studies 
Drug leakage study 
It is clear from the results obtained that the niosomes have shown a 
minimum drug loss at refrigerated condition and fairly high 
retention of drug inside the vesicles was observed these results were 
concordant to Asthana et al. (2016) [5]. At this low temperature 
condition only 2.797 % of drug was lost as compared to storage at 
25 °C and 37 °C which led to 4.113 % and 5.125 % drug loss 
respectively at the end of 35 d results shown in (table 6). The higher 
amount of drug leakage at elevated temperature may be related to 
the degradation of lipid constituting the bilayers resulting in defect 
in membrane packing and loss of overall rigidity that makes them 
leaky. So it can be concluded from the above discussion that the 
niosomal formulation should be stored at lower temperatures to 
minimize drug loss. 
 
Table 6: Drug leakage studies of niosomal formulation NMS7 at various temperature conditions 
Time(days) 4 °C 25 °C 37 °C 












Initialload 100 - 100 - 100 - 
7 99.529 0.472 98.517 1.483 98.113 1.887 
14 98.7195 1.281 97.405 2.596 96.898 3.101 
21 98.214 1.786 97.000 3.000 96.292 3.708 
28 97.607 2.393 96.696 3.303 95.988 4.012 
35 97.203 2.797 95.887 4.113 94.876 5.125 
Khan et al. 
Int J Pharm Pharm Sci, Vol 12, Issue 3, 15-22 
21 
CONCLUSION 
The present research was conducted to build up an appropriate drug 
delivery system for delivery of famotidine. The niosomal suspension 
of famotidine was successfully prepared from thin film hydration 
technique. The characterization of the drug loaded niosomal 
suspension by SEM and TEM revealed spherical shape with 
homogienety in all optimized formulations with polydispersity 
values well suited for oral drug delivery, zeta potential and vesicle 
size values reveal that the formulations have good stability with 
vesicle size in nano range. The kinetics of drug release reveal that 
the formulations show a better fit to zero order release pattern 
which predicts a controlled release pattern of drug from niosomes. 
The In vivo study clearly shows a higher Cmax value as compared to 
free drug which is indicative of improvement in bioavailability 
furthermore the AUC obtained in case of best formulation clearly 
shows a fourfold increase which shows a prolonged duration of drug 
release for more than 24 h making the formulation suitable for once 
a day administration thus improving the patient compliance and 
reducing the problems associated with peak and valley curves in 
plasma drug concentrations. The stability studies confirm that the 
formulations are most stable when kept at lower temperature. Thus 
it can be concluded that the niosomes can be successfully employed 
for prolonging the drug release and can prove to be a better drug 
delivery option. 
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